京éœå€§åŠ(京倧)ã®ç ç©¶ã°ã«ãŒãã¯ãããŠã¹ã§å€èœæ§å¹¹çްèã§ããES现èãšiPS现èãåµåã粟åãäœãå ãšãªãå§åçæ®çŽ°èã«è©Šéšç®¡å ã§ååãããŠãããããããšã«å¥åžžãªç²Ÿåãšãã®åå«ãåŸãããšã«æåããããšãçºè¡šããã
åææã¯å倧倧åŠé¢å»åŠç ç©¶ç§ã®æè€éçŽææãšæå 圊è¬åž«ãã®ç ç©¶ã°ã«ãŒãã«ãããã®ã§ãç±³åœç§åŠèªãCellãã®ãªã³ã©ã€ã³éå ±çã§å ¬éãããã
iPS现èäœè£œå¹çã®æ¹åãããã¯ã¿ãŒã®ã²ãã ãžã®çµèŸŒã¿ã䌎ããªããããå®å šãªiPS现èäœè£œæè¡ã®éçºãªã©ãé²ããããŠãããä»åŸãiPS现èãé«ãå¹çã§åçŸæ§ãããå»åŠçã«æçšãªçްèã«ååãããæè¡ã®éçºãéèŠã«ãªã£ãŠãããšèããããŠãããããã®äžæ¹ã§ãäœçްèãåååã®iPS现èã«æ»ã(ãªããã°ã©ãã³ã°)ååæ©æ§ã«é¢ããŠã¯ãå€ãã®ç¹ãæªè§£æã®ãŸãŸãšãªã£ãŠããã
ãã®ãªããã°ã©ãã³ã°éçšã«é¢äžããååæ©æ§ãè§£æããããšã¯ãiPS现èäœè£œã®ãããªãå¹çåã»ç°¡äŸ¿åã«ã€ãªãããšèããããŠãããäžã§ãçæ®çŽ°èç³»åã¯ããããå«ãå€çްèçç©ãæ§æããçäœå ã®çްèç³»èã®äžã§ãæã现èã®å€èœæ§ã现èãªããã°ã©ãã³ã°ã«é¢é£ãããã®ã§ãããšèããããŠããããŸããçäœã«ããã现èç³»èååã»æ©èœç¶ææ©æ§ã®æ£ç¢ºãªçè§£ãšããããã®éçšãèŠå®ãããšãã²ãã ç¶æ ã®æž¬å®ãå¯èœã«ããããšã¯ããã®åéã®ç ç©¶ãããã«çºå±ããããã®ãšèããããŠããã
åç ç©¶ã°ã«ãŒãã§ã¯ä»åãããŠã¹ã®çºçã«ãããŠçæ®çްèãäœãããéçšã«èµ·ããéºäŒåçºçŸãããªããã°ã©ãã³ã°çŸè±¡ãäœå€å¹é€ç³»ã§åæ§ç¯ããããšãç®çã«ããŠå®éšãè¡ã£ããæ¹æ³ãšããŠã¯ãçæ®çŽ°èãå«ããã»ãŒå šãŠã®çްèã«ãªãããES现èãiPS现èãææãšããŠãããããäœå€å¹é€ã«ãããŠå§åçæ®çŽ°èã«ååãããããšã詊ã¿ããææãšããŠã¯ãå§åçæ®çŽ°èã«ç¹ç°çã«çºçŸããéºäŒåã§ããBlimp1ãšStellaã®çºçŸå¶åŸ¡äžã«ãèå ããã±ã質ãçºçŸããããéºäŒåæ¹å€ããES现èãçšããŠãããããã«ããå§åçæ®çŽ°èã«ååãã现èã¯èå ããã±ã質ã«ããå ãçºãããããèå é¡åŸ®é¡äžã§å®¹æã«èгå¯ã§ããããã«ãªã£ãã
ãããŸã§ããES现èããå§åçæ®çŽ°èãååãããŠäœå€ã§å¹é€ããæè¡éçºã¯è¡ãããŠãããã粟åãå¥åžžãªåå«ãåµåºã§ããå§åçæ®çŽ°èãäœå€å¹é€ã§äœè£œã§ããæåäŸã¯ãªãã£ãããã®åå ãšããŠãé©åãªES现èã®ååå¹é€æ¡ä»¶ãæŽããããªãã£ãããšãæãããããç¹ã«äœå ã®çºçã§ã¯ãå§åçæ®çŽ°èã¯ãšããã©ã¹ããšåŒã°ãã现èéå£ããæé·å åBMP4ã«ããèªå°ããããããããŸã§ã®ç ç©¶ã§ã¯ãES现èãããšããã©ã¹ããŸã§ã®ååå¹é€æ¡ä»¶ã®æ€èšãäžååã§ãã£ãããšãããäžæãå¹é€ã§ããã«ãããä»åã®ç ç©¶ã§ã¯ãES现èãæé·å åbFGFãšActivinããã³KSRã§å¹é€ãããšããæ¹æ³ãéçºãããšããã©ã¹ãã«è¿ãç¶æ ã®çްèãäœè£œããããšã«æåããŠãããå现èã¯ããšããã©ã¹ãæ§çްè(Epiblast-like cells:EpiLCs)ãšåä»ãããããšããã
ããã«ç ç©¶ã°ã«ãŒãã§ã¯ãåEpiLCsãBMP4ã«ããåºæ¿ããåŸãèå ããã±ã質ã®çºçŸãææšã«å§åçæ®çŽ°èæ§çŽ°è(PGC(Primordial Germ Cell)-like cells:PGCLCs)ãåé¢ãããã®éºäŒåçºçŸãã¿ãŒã³ã調ã¹ããšãããäœå ã®å§åçæ®çŽ°èãšã»ãŒåçã§ããããšã確èªããã
ãŸãPGCLCsã®èªå°å¹çã¯BMP4åºæ¿åŸ2æ¥ç®ã§çŽ40%以äžã«éãããããŸã§ã®ç ç©¶(3%以äž)ãšæ¯ã¹ãŠãé£èºçã«ãã®å¹çãåäžããããšã確èªãããããã®PGCLCsããçæ®çŽ°èãæããªãc-kitå€ç°ããŠã¹ã®ç²Ÿå·£ã«ç§»æ€ããçµæãPGCLCsã¯ç²Ÿå圢æãéå§ãç§»æ€åŸçŽ10é±éåŸã«ç²ŸåãŸã§ååããåµçްè質å ç²Ÿåæ³šå ¥æ³(ICSI)ã«ããåµåãšæç²ŸãããåŸãããå粟åµã仮芪ã®éããŠã¹ã«ç§»æ€ããçµæãäžçã§åããŠäœå€å¹é€ã§ååãããå§åçæ®çŽ°èã«ç±æ¥ããå¥åžžãªããŠã¹ãåŸãããšã«ãæåãããšããã
åããŠã¹ã¯æ£åžžã«çºéããééãšãã«çæ®èœåãããããšã確èªãããã
å ããŠç ç©¶ã°ã«ãŒãã§ã¯ãå§åçæ®çŽ°èã«çºçŸããè¡šé¢æåSSEA1ãšIntegrin-β3ãèªèããæäœãçšããããšã«ãããèå ããã±ã質ãæããªãES现èãããPGCLCsãåé¢ããããšã«æåããŠããããã®PGCLCsãããå¥åžžãªããŠã¹ãåŸãããã»ããåæ§ã®å¹é€æ¡ä»¶ã«ãããiPS现èã§ãPGCLCsã®ååã粟åã®äœè£œãå¥åžžããŠã¹ã®ååŸã«æåãããšããã
ãªããåææã¯åºç€ããã³å¿çšé¢ã®åæ¹ã«ãããŠå€§ããªå¹æãæåŸ ã§ãããšç ç©¶ã°ã«ãŒãã§ã¯èª¬æããŠãããåºç€é¢ã«ãããŠã¯ãçæ®çŽ°è圢æã¡ã«ããºã ã®è§£æããšãã²ãã ã®è©³çްãªè§£æãå¯èœã«ãªãããšãæãããããäœå ã®å§åçæ®çŽ°èã¯éåžžã«å°æ°ã§ããããŸã§ãã®ãšãã²ãã ã®è§£æãå°é£ã§ãã£ãããä»åã®äœå€å¹é€æè¡ãçšããããšã§ã倿°ã®PGCLCsãåŸãããšãå¯èœã«ãªããå§åçæ®çŽ°èãäœçްèåããå€èœæ§å¹¹çްèåã«ãªããã°ã©ãã³ã°ãããéçšã®ãšãã²ãã ãè§£æããäžã§ååãã€è³é©ãªçްèãäŸçµŠã§ããããã«ãªããšããã
ãŸããå¿çšé¢ã«ãããŠã¯ãäžåŠçã®åå ç©¶æãæ²»çæ³ã®éçºã«å¹æãæåŸ ã§ãããšãããåäœå€å¹é€æè¡ã§ã¯ãäœå ã«ãããå§åçæ®çŽ°èã®çºçããES/iPS现èãèµ·ç¹ãšããŠå¿ å®ã«åçŸã§ããããšããããã®å¹é€ç³»ãçºçã¢ãã«ãšããŠçšããŠãå§åçæ®çŽ°èã®çºçã«å¿ èŠãªéºäŒåã®åé¢ãå¯èœã§ããããããã®éºäŒåã¯ããã®äžåŠçã®åå éºäŒåãšãªã£ãŠããå¯èœæ§ãããã»ããåäœå€å¹é€æè¡ãå¿çšããããšã§ãããES现èã«ãã質ã®é«ãå§åçæ®çŽ°èãååèªå°ã§ããå¯èœæ§ãé«ãŸããšããã



